Drug Profile


Alternative Names: Infasurf

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ony
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neonatal respiratory distress syndrome
  • No development reported Acute lung injury
  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 29 Mar 2017 Phase-III clinical trials in Neonatal respiratory distress syndrome (In neonates) in USA (Inhalation, Aerosol) (NCT03058666)
  • 28 Feb 2017 Ony plans a phase III trial for Respiratory distress syndrome (In neonates) (NCT03058666)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top